Multi-phased presentation of breast cancer
(i) The importance of a clinical period for breast cancer. It is based on the size of the tumour, the availability of lymphocytes and the presence of remote transfer. (ii) Specific phases • Early (0 and I): No. 0 is in situ, cancer cells are confined to the catheters of the mammary or the leaves and have not broken through the substrate, at which point the tumor is at a very early stage and is usually better predicted. Breast cancer I, typically tumours of less than 2 cm in diameter, with no lymphocytes transfer and remote transfer. Patients at this stage can often be surgically excised of tumours, with higher rates of cure. • Medium term (phases II and III): stage II breast cancer, tumour size of 2 – 5 cm, or tumours of less than 2 cm with a lymphoma transfer; also includes tumours of more than 5 cm but no lymphoma transfer. Phase III is a further development of tumours, which may be accompanied by lymphoma lymphoma condensation, or co-side lymphoma transfer. Breast cancer treatment in the medium term is relatively complex and often requires a variety of treatments, including comprehensive surgery, chemotherapy and treatment. • Late (IV): the fourth stage is when breast cancer occurs in a remote transfer, e.g. to organs such as lungs, liver, bones and brain. Patients at this stage are seriously ill, and the treatment is aimed mainly at abating symptoms, extending the life cycle and improving the quality of life, with more use of whole-body treatment, such as endocrine treatment, target treatment and chemotherapy. ii. The stratification of breast cancer (i) based on pathological tissue type — non-immersional cancer: including intraductal cancer and in situ cancer of small leaves, which, as mentioned above, does not break the base membrane, which is better. The survival rate of such cancers is high if they are detected and treated at an early stage. Early leachate cancer: Early leachate catheter cancer and early leachate leaf cancer. Cancer cells begin to break through the base membrane and are immersed in the mesmbrane, but in a relatively small area, which is still relatively early, with better results from timely treatment. Special leachate cancers such as breast cancer, marrow cancer (with a large number of lymphocytes immersed), small tubing cancers, gland cystal cancer, etc. This model is highly differentiated and is well advanced. Their biological behaviour has certain characteristics, and treatment programmes need to be adapted to specific circumstances. Vaccination of non-special cancers: is the most common type of breast cancer, including immersion of leaf, immersion of catheter, etc. This type of breast cancer, which accounts for the majority of breast cancers, is relatively poor and prone to diversion and requires active and integrated treatment. (ii) Based on molecular stratification — Luminal A type: positive estrogen receptor (ER) and pregnancy hormone receptor (PR) of this type of breast cancer, negative human skin growth factor (HER-2), low expression Ki-67. It is better planned, endocrine treatment is effective and less sensitive to chemotherapy and is generally preferred. • Luminal B type: ER and/or PR positive, Her – 2 positive or negative, Ki – 67 high expression. If HeR – 2 is positive, a target can be used on an endocrinological basis; if HeR – 2 is negative, a combination of endocrine treatment can be used. • Her – 2 overexpression: ER, PR negative, Her – 2 positive. This type of breast cancer is sensitive to the target treatments, such as the one-size-fits-all drug, and often requires joint chemotherapy treatment. • Three-negative breast cancers: ER, PR, HER – 2 all negative. This type of breast cancer is highly invasive, has poor prognosis, lacks effective endocrine and target-oriented treatment and relies mainly on chemotherapy, but a number of new treatment studies are under way. The knowledge of the stratification of breast cancer helps doctors to develop accurate treatment programmes for patients, while at the same time allowing patients to better understand their condition and to cooperate actively with them.
Breast cancer
